Together with our partners we have been featured in a Wevolver article on integrated photonics, sponsored by PhotonDelta. The article summarizes the photonic biosensor technology and their usage for cost-effective mass application of biosensors for bed-side testing.Read the whole article here.

A team of Compamed, the leading trade fair for medical technology, visited us at our facilities on the Wageningen University Campus. Our colleagues, Dr. Anke Schütz-Trilling and Hans Dijk, have presented our most recent project: The development of a biosensor based on the photonic biochip, which can be used as a fast, reliable and inexpensive mass test for covid-19. Check out the video (3min) here.

This week's issue of Bits&Chips offers a great article on Surfix's development of a SARS-CoV-2 test, based on photonic biochips and selective nano-coatings. The three Dutch companies Surfix, Lionix and Qurin are developing a biochip along with Photondelta in a public- private partnership to unloc the potential of integrated photonics for corona testing. Read the full article here.

On May 11th, 2020, Luc Scheres presented at the EPIC Online Technology Meeting on Biosensors. You can watch his talk here. (starting time 28:34). Our CTO Luc talks about the work Surfix is doing in the fields of Photonic Biosensors, Nanocoatings, COVID-19 etc. Enjoy! 

Surfix B.V., together with its shareholders Qurin Diagnostics B.V. and LioniX International B.V., already successfully developing bio-photonic nanochips for cancer detection and other applications, today announce an accelerated development plan to allow mass-scale COVID-19 diagnosis and immunity detection with the financial support and in close collaboration with PhotonDelta.

The desktop testing device will yield reliable test results within 5 minutes and is scheduled to be available for commercial exploitation within 6-9 months. The device will be built around a photonic biochip using LioniX’ mature and proven silicon nitride based integrated optics technology (TriPleX™), a key technology within the PhotonDelta ecosystem. The surface functionalization and biochemical assay development are provided by Surfix and Qurin Diagnostics, respectively. The combination of these disciplines enables a successful, fast and accurate virus detection platform. The development will be supported by and in tight collaboration with Photon Delta (a Dutch public private partnership). The PhotonDelta support will be both in co-funding as in further future upscaling and exploitation.

Qurin Diagnostics, Surfix and LioniX International are already working together closely on early cancer detection and have realized an ultra-sensitive biochip sensor array which will be applied for early cancer detection using urine as a liquid biopsy.

Surfix and the HEIDENHAIN Group demonstrate guided liquid flow in a glass microfluidic channel by a patterned hydrophobic nanocoating.